HIV Infections Clinical Trial
Official title:
Understanding the Role of Social Networks in Methadone Maintenance Treatment Retention and Antiretroviral Therapy Adherence Among People Who Inject Drugs in Tanzania
Investigators will adapt the Brief Social Behaviour and Network Therapy (B-SBNT) intervention developed to facilitate recovery among people receiving medication-assisted treatment for opioid use disorder in the United Kingdom. The B-SBNT involves families and the wider social networks of people receiving medications for opioid use disorder to support recovery. Key components of the intervention include: mapping the social networks of clients; inviting others identified through the mapping to participate in the intervention; building communication strategies with network members; and developing joint activities with network members. In the original B-SBNT, the intervention is delivered by therapists/clinicians who undergo training. Investigators will pilot test the adapted version of this intervention with a maximum of 80 people: 20 current clients receiving methadone maintenance treatment (MMT) at the Muhimbili National Hospital (MNH) Medically-Assisted Treatment (MAT) Clinic and up to 60 social support persons identified by recruited MMT clients. The pilot will assess the social network intervention's acceptability and feasibility.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | September 2024 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria for MMT client participants in the intervention pilot: - 18 years old or older, - currently enrolled in the MAT program at the Muhimbili MAT clinic, - prescribed methadone for the past 3 months, - received a positive test result for heroin, cannabis or alcohol use in the past 3 months, - provide consent for trial participation. Inclusion criteria for social support persons in the intervention pilot: - 18 years old or older, - identified as a social support person of a MMT client participating in the pilot trial - lives in Dar es Salaam, - provide consent for trial participation. Exclusion Criteria: - Does not meet inclusion criteria |
Country | Name | City | State |
---|---|---|---|
Tanzania | Muhimbili National Hospital | Dar Es Salaam |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins Bloomberg School of Public Health | Muhimbili University of Health and Allied Sciences, National Institute on Drug Abuse (NIDA) |
Tanzania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of participants who attend week 1 intervention session | Intervention session attended by participants (MMT clients and identified social support persons) | Week 1 of intervention | |
Primary | Proportion of participants who attend week 2 intervention session | Intervention session attended by participants (MMT clients and identified social support persons) | Week 2 of intervention | |
Primary | Proportion of participants who attend week 3 intervention session | Intervention session attended by participants (MMT clients and identified social support persons) | Week 3 of intervention | |
Primary | Proportion of participants who attend week 4 intervention session | Intervention session attended by participants (MMT clients and identified social support persons) | Week 4 of intervention | |
Primary | Proportion of participants who attend week 5 intervention session | Intervention session attended by participants (MMT clients and identified social support persons) | Week 5 of intervention | |
Primary | Proportion of participants who attend week 6 intervention session | Intervention session attended by participants (MMT clients and identified social support persons) | Week 6 of intervention | |
Primary | Proportion of sessions with > 80% fidelity | An Integrity of Intervention checklist will be created for the study to assess intervention delivery fidelity, including facilitator adherence to manual instructions, specifically information and content that is intended to be covered for each session. An intervention fidelity score that ranges from 0 to 100%, with 100% indicating 100% fidelity or 100% adherence to intervention manual, will be created. | Post-intervention up to 1 month | |
Primary | Perceptions of intervention fidelity | Perceptions of intervention fidelity will be assessed through qualitative interviews with facilitators and participants. Perceptions of intervention fidelity, including facilitators and barriers to intervention fidelity will be summarized thematically. | Post-intervention up to 1 month | |
Primary | Intervention session acceptability score (week 1) | Acceptability of interventions sessions, specifically content, activities, and delivery (i.e., group or individual format, social support persons involvement), will be measured through the exit surveys developed by the study team. Each of the four exit survey items will be assessed as 0 for not acceptable and 1 for acceptable. Scores will be created for each participant and averaged over all intervention sessions. | Week 1 of intervention | |
Primary | Intervention session acceptability score (week 2) | Acceptability of interventions sessions, specifically content, activities, and delivery (i.e., group or individual format, social support persons involvement), will be measured through the exit surveys developed by the study team. Each of the four exit survey items will be assessed as 0 for not acceptable and 1 for acceptable. Scores will be created for each participant and averaged over all intervention sessions. | Week 2 of intervention | |
Primary | Intervention session acceptability score (week 3) | Acceptability of interventions sessions, specifically content, activities, and delivery (i.e., group or individual format, social support persons involvement), will be measured through the exit surveys developed by the study team. Each of the four exit survey items will be assessed as 0 for not acceptable and 1 for acceptable. Scores will be created for each participant and averaged over all intervention sessions. | Week 3 of intervention | |
Primary | Intervention session acceptability score (week 4) | Acceptability of interventions sessions, specifically content, activities, and delivery (i.e., group or individual format, social support persons involvement), will be measured through the exit surveys developed by the study team. Each of the four exit survey items will be assessed as 0 for not acceptable and 1 for acceptable. Scores will be created for each participant and averaged over all intervention sessions. | Week 4 of intervention | |
Primary | Intervention session acceptability score (week 5) | Acceptability of interventions sessions, specifically content, activities, and delivery (i.e., group or individual format, social support persons involvement), will be measured through the exit surveys developed by the study team. Each of the four exit survey items will be assessed as 0 for not acceptable and 1 for acceptable. Scores will be created for each participant and averaged over all intervention sessions. | Week 5 of intervention | |
Primary | Intervention session acceptability score (week 6) | Acceptability of interventions sessions, specifically content, activities, and delivery (i.e., group or individual format, social support persons involvement), will be measured through the exit surveys developed by the study team. Each of the four exit survey items will be assessed as 0 for not acceptable and 1 for acceptable. Scores will be created for each participant and averaged over all intervention sessions. | Week 6 of intervention | |
Primary | Intervention feasibility assessed by qualitative interviews | Intervention feasibility will be assessed through qualitative interviews with intervention facilitators and participants. Questions will include experiences delivery or participating in the intervention, barriers and facilitators to delivering the intervention or participating in the intervention session, and recommendations for improvements. | Post-intervention up to 1 month | |
Secondary | Changes in missed methadone doses | Number of missed methadone doses in the past 30 days as assessed by MMT client clinical records | Pre- and post-intervention up to 1 month | |
Secondary | Changes in antiretroviral therapy (ART) adherence | ART pharmacy refills in the past 3 months | Pre- and post-intervention up to 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |